MAIA Biotechnology (MAIA) Projected to Announce Earnings on Friday

Key Points

• MAIA Biotechnology is expected to report Q3 2026 results on November 6, with analysts forecasting a loss of $0.13 per share. The company reported a larger-than-expected loss of $0.13 per share in the prior quarter.
• MAIA shares opened at $1.18, near the lower end of their 52-week range of $0.87 to $3.19. The company has a market capitalization of approximately $72.9 million.
• Insiders have been buying shares: CEO Vlad Vitoc and Director Ramiro Guerrero recently increased their holdings, while insiders collectively purchased 258,078 shares worth about $352,426 over the past 90 days.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) will likely be releasing its Q3 2026 resultson Friday, November 6th. Analysts expect the company to post earnings of ($0.13) per share for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, analysts expect MAIA Biotechnology to post ($0.54) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

MAIA Biotechnology Price Performance

MAIA Biotechnology stock opened at $1.18 on Friday. MAIA Biotechnology has a 1-year low of $0.87 and a 1-year high of $3.19. The firm has a market capitalization of $72.85 million, a P/E ratio of -1.90 and a beta of 0.27. The company's 50-day moving average is $1.25 and its 200 day moving average is $1.46.

Insider Activity at MAIA Biotechnology

In other MAIA Biotechnology news, CEO Vlad Vitoc purchased 73,000 shares of MAIA Biotechnology stock in a transaction dated Monday, September 14th. The shares were purchased at an average cost of $1.37 per share, for a total transaction of $100,010.00. Following the completion of the acquisition, the chief executive officer owned 1,049,121 shares in the company, valued at $1,437,295.77. This represents a 7.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ramiro Guerrero purchased 78,239 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average cost of $1.39 per share, with a total value of $108,752.21. Following the completion of the purchase, the director directly owned 689,081 shares in the company, valued at $957,822.59. The trade was a 12.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 258,078 shares of company stock valued at $352,426 in the last 90 days. Company insiders own 19.81% of the company's stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA's lead investigational product is THIO, also known as 6-thio-2'-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.